Number of pages: 100 | Report Format: PDF | Published date: 01 February, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
Report Attribute |
Details |
Market size value in 2021 |
US$ 3.0 billion |
Revenue forecast in 2030 |
US$ 6.7 billion |
Growth Rate |
CAGR of 8.5% from 2022 to 2030 |
Base year for estimation |
2021 |
Forecast period |
2022-2030 |
Historical Year |
2020 |
Segments covered |
Drug Type, Treatment Type, End User and Region. |
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global amyotrophic lateral sclerosis market was valued at US$ 3.0 billion in 2021, and is expected to witness a CAGR of 8.5% during the forecast period from 2022 to 2030.
Market Fundamentals
Amyotrophic lateral sclerosis (ALS), sometimes known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the central nervous system that govern voluntary muscles. Muscle twitching, stiffness, and weakness due to a decrease in the size of muscles in the legs or arms are some of the usual symptoms. Approximately 50% of the patients with ALS may lose their ability to swallow, breathe, speak, walk, and use their hands. According to the National Institute of Neurological Disorders and Stroke (NINDS), patients with ALS frequently die from respiratory failure within 3-5 years of progressive paralysis. It further indicates that sporadic ALS is the most common, accounting for 90% to 95% of all cases in the United States, while familial ALS accounts for the remainder.
[63356345]
Market Dynamics
With rising obesity rates worldwide, the necessity for a comprehensive examination of this healthcare issue prompted the creation of this report. Key market drivers include increased binge eating and junk food consumption, apathy toward regular exercise, and rising stress levels. The paper goes into greater detail regarding these topics, focusing on the growing need for Amyotrophic Lateral Sclerosis (ALS) Treatment. Furthermore, an increase in the launch of novel pharmaceuticals, an increase in healthcare expenditure, and well-established healthcare infrastructure are projected to boost market expansion. The growth in strategic collaborations between major organizations and research institutes for the development of Amyotrophic lateral sclerosis (ALS) treatment, as well as the increase in government initiatives to examine rare disease research and FDA approvals, are likely to open a slew of new possibilities for this amyotrophic lateral sclerosis treatment.
Market Ecosystem
The global amyotrophic lateral sclerosis market has been analyzed from four perspectives: Drug Type, Treatment Type, End User and Region.
Amyotrophic Lateral Sclerosis Market by Drug Type
[42424211]
Based on drug type, the global amyotrophic lateral sclerosis market has been segmented into sporadic amyotrophic lateral sclerosis (ALS) and familial amyotrophic lateral sclerosis (ALS). During the forecast period, the sporadic ALS segment shall dominate the global amyotrophic lateral sclerosis market. Sporadic ALS is the most common, accounting for 90- 95% of all instances in the United States, with the familial kind accounting for the remainder. On the contrary, familial ALS is the fastest-growing segment. Familial ALS (FALS) is a hereditary condition in which each offspring has a 50% risk of inheriting the genetic mutation and developing the disorder. The deficiency is most typically seen in the C9ORF72 gene in 25-40% of persons with familial ALS. A mutation in this gene also causes frontotemporal dementia (FTD), which can develop alongside ALS as a comorbidity known as ALS-FTD.
Amyotrophic Lateral Sclerosis Market by Treatment Type
Based on treatment type, the global amyotrophic lateral sclerosis market has been segmented into medication therapy, stem cell therapies, respiratory therapy, speech therapy, and others. The medication physical therapy segment dominates the market. It includes two FDA-approved medications for treatment, Rlutek (riluzole) and Radicava (edaravone). Steam Cell Therapies are also projected to develop significantly as the desire for new techniques and improved treatment increases.
Amyotrophic Lateral Sclerosis Market by End User
Based on the end users, the global amyotrophic lateral sclerosis market has been segmented hospitals, specialty centers, research and academic institutes, and others. The hospital segment dominated the market during the forecast period, and this trend will continue during the projection period. Patients are increasingly favoring hospital pharmacies over others end users. This can be accredited to simple and quick access to a diverse choice of drugs and sufficient products provided by hospitals.
Amyotrophic Lateral Sclerosis Market by Region
Based on region, the global amyotrophic lateral sclerosis market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to dominate a significant market share in the global amyotrophic lateral sclerosis (ALS) Treatment Market due to the increasing incidence of amyotrophic lateral sclerosis diseases, rising demand for ALS drugs, rising healthcare expenditure, well-established healthcare infrastructure, favorable reimbursement policies, and technological advancements. Furthermore, the presence of a senior population exacerbates these issues. The majority of people over the age of 50 are more likely to develop this disorder, according to the Centres for Disease Control and Prevention (CDC) and the Organization for Toxic Substances and Disease Registry (ATSDR), which is expected to fuel the demand in the Asia Pacific amyotrophic lateral sclerosis market.
Competitive Landscape
Some of the prominent market players in the global amyotrophic lateral sclerosis market include
Strategic Development
The Asia Pacific is the key growth region in the global amyotrophic lateral sclerosis market
The rising prevalence of amyotrophic lateral sclerosis and the growing geriatric population are the key drivers of the global amyotrophic lateral sclerosis market.
Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen Inc., F.Hoffmann-La Roche AG., Jazz Pharmaceuticals, Taiwan Biotech Co. Ltd., and Novartis AG
The global amyotrophic lateral sclerosis market is expected to clock US$ 6.7 billion by 2030.
The global amyotrophic lateral sclerosis market is expected to witness a CAGR of 8.5% during the forecast period from 2022 to 2030.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.